View Older Stories View More Recent Stories

Jul 10, 2025 04:05PM Illumina to Announce Second Quarter 2025 Financial Results on Thursday, July 31, 2025
May 14, 2025 04:05PM Illumina To Webcast Upcoming Investor Conference
Apr 16, 2025 08:45AM Global AI Diagnostics Market to Reach $8.54 Billion By 2033 as Industry Sees Increasing R&D and Strategic Collaborations
Apr 10, 2025 04:05PM Illumina to Announce First Quarter 2025 Financial Results on Thursday, May 8, 2025
Feb 18, 2025 04:05PM Illumina To Webcast Upcoming Investor Session at the Advances in Genome Biology and Technology (AGBT) Conference
Jan 9, 2025 04:22PM Illumina to Announce Fourth Quarter and Full Year 2024 Financial Results on Thursday, February 6, 2025
Dec 4, 2024 04:07PM Illumina To Webcast Upcoming Investor Conference
Dec 4, 2024 03:30AM Synaffix Licenses Metal-Free Click Chemistry Technology to Illumina for Next-Generation DNA Sequencing Applications
Nov 6, 2024 04:05PM Illumina To Webcast Upcoming Investor Conferences
Oct 7, 2024 04:05PM Illumina to Announce Third Quarter 2024 Financial Results on Monday, November 4, 2024
Sep 3, 2024 05:20AM European Court of Justice rules in favor of Illumina (ILMN) in jurisdictional appeal
Sep 3, 2024 03:59AM European Court of Justice rules in favor of Illumina in jurisdictional appeal
Aug 13, 2024 11:00AM Illumina (ILMN) announces strategy to accelerate value creation
Aug 13, 2024 11:00AM Illumina announces strategy to accelerate value creation
Aug 6, 2024 04:05PM Illumina Reports Financial Results for Second Quarter of Fiscal Year 2024
Jul 18, 2024 04:05PM Illumina to Present Upcoming Strategy Update
Jul 11, 2024 04:05PM Illumina to Announce Second Quarter 2024 Financial Results on Tuesday, August 6, 2024
Jun 24, 2024 04:05PM Illumina (ILMN) completes divestiture of GRAIL
Jun 24, 2024 04:05PM Illumina completes the divestiture of GRAIL
Jun 3, 2024 05:23PM Illumina (ILMN) Approves Spin-off of GRAIL, Declares Dividend
Jun 3, 2024 05:22PM Illumina Board of Directors approves spin-off of GRAIL; declares spin-off dividend of GRAIL shares
Jun 3, 2024 07:12AM Illumina (ILMN) appoints Everett Cunningham Chief Commercial Officer
Jun 3, 2024 07:11AM Illumina appoints Everett Cunningham Chief Commercial Officer
May 20, 2024 04:07PM Illumina (ILMN) Appoints Anna Richo to its Board
May 20, 2024 04:05PM Anna Richo joins Illumina's Board of Directors
May 15, 2024 04:05PM Illumina To Webcast Upcoming Investor Conference
May 6, 2024 06:28PM Illumina publicly files Form 10 registration statement ahead of planned divestiture of GRAIL
May 3, 2024 09:25AM Illumina To Webcast Upcoming Investor Conference
May 2, 2024 04:05PM Illumina Reports Financial Results for First Quarter of Fiscal Year 2024
Apr 4, 2024 05:00PM Illumina to Announce First Quarter 2024 Financial Results on Thursday, May 2, 2024
Feb 8, 2024 04:05PM Illumina Reports Financial Results for Fourth Quarter and Fiscal Year 2023
Feb 1, 2024 09:00AM Curative Insurance Company Adds GRAIL’s Galleri® Test to Member Benefits for Multi-Cancer Early Detection
Jan 15, 2024 07:00AM Concentric by Ginkgo and Illumina collaborate to deploy biosurveillance technologies around the world
Jan 9, 2024 09:02AM Illumina (ILMN) Prelim. Q4 Revenue Tops Consensus
Jan 9, 2024 09:00AM Illumina Announces Preliminary Financial Results for Fourth Quarter and Fiscal Year 2023
Jan 5, 2024 04:24PM ILMN FINAL DEADLINE ALERT: ROSEN, A LEADING LAW FIRM, Encourages Illumina, Inc. Investors to Secure Counsel Before Important January 9 Deadline in Securities Class Action – ILMN
Jan 5, 2024 09:15AM Illumina (ILMN) Expand Collaboration with Janssen for Molecular Residual Disease Cancer Test
Jan 5, 2024 09:15AM Illumina expands collaboration with Janssen to advance molecular residual disease cancer test
Jan 4, 2024 04:05PM Illumina to Announce Fourth Quarter and Full Year 2023 Financial Results on Thursday, February 8, 2024
Jan 4, 2024 09:15AM The Alliance for Genomic Discovery welcomes Bristol Myers Squibb, GSK, and Novo Nordisk
Dec 28, 2023 11:50AM ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Illumina, Inc. Investors to Secure Counsel Before Important January 9 Deadline in Securities Class Action – ILMN
Dec 24, 2023 01:19PM ROSEN, TRUSTED NATIONAL TRIAL COUNSEL, Encourages Illumina, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action – ILMN
Dec 19, 2023 04:05PM Illumina To Webcast Upcoming Investor Conference
Dec 18, 2023 06:08PM ROSEN, LEADING INVESTOR COUNSEL, Encourages Illumina, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action – ILMN
Dec 17, 2023 02:44PM Illumina (ILMN) to divest Grail
Dec 17, 2023 02:37PM Illumina Announces Decision to Divest GRAIL
Dec 11, 2023 07:36PM ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages Illumina, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action – ILMN
Dec 11, 2023 01:00PM Illumina (ILMN) submits Form 10 to the Securities and Exchange Commission related to its potential divestiture of GRAIL
Dec 11, 2023 12:57PM Illumina submits Form 10 to the Securities and Exchange Commission
Dec 7, 2023 07:20PM ROSEN, LEADING INVESTOR COUNSEL, Encourages Illumina, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – ILMN
View More Recent Stories View Older Stories